Clincosm LogoSign in Get a demo

Determining Clinical Trial Experiences of Lung Cancer Patients

Sponsor
Power Life Sciences Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05760170
Collaborator
(none)
500
Enrollment
24
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This trial will admit a wide range of data on the clinical trial experience of lung cancer patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future lung cancer patients.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    An Observational Study to Determine Experience Patterns in Participants of Lung Cancer Clinical Trials
    Anticipated Study Start Date :
    Mar 25, 2023
    Anticipated Primary Completion Date :
    Mar 25, 2024
    Anticipated Study Completion Date :
    Mar 25, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Number of lung cancer patients who decide to enroll in a clinical trial [3 months]

    2. Rate of patients who remain in a lung cancer clinical trial to trial completion [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patient has been diagnosed with lung cancer

    • Patient has self-identified as planning to enroll in an observational clinical trial

    • Patient is a minimum of 18 years or older

    Exclusion Criteria:

    • Pregnant or nursing patients

    • Inability to perform regular electronic reporting

    • Patient does not understand, sign, and return consent form

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Power Life Sciences Inc.

    Investigators

    • Study Director: Michael B Gill, Power Life Sciences Inc.

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    Power Life Sciences Inc.
    ClinicalTrials.gov Identifier:
    NCT05760170
    Other Study ID Numbers:
    • 81893664
    First Posted:
    Mar 8, 2023
    Last Update Posted:
    Mar 8, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Power Life Sciences Inc.
    lung cancer
    Additional relevant MeSH terms:
    Lung Neoplasms

    Study Results

    No Results Posted as of Mar 8, 2023